Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation

Seiji Kojima, Jun Inaba, Ayami Yoshimi, Yoshiyuki Takahashi, Nobuhiro Watanabe, Kazuko Kudo, Keizo Horibe, Naoko Maeda, Koji Kato, Takaharu Matsuyama

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We report a favourable outcome in 15 patients with severe aplastic anaemia (SAA) who were <20 years of age and who underwent bone marrow transplantation (BMT) from a human leucocyte antigen (HLA)-matched unrelated donor. All patients were non-responders to intensive immunosuppressive therapy (IST) and were multiply transfused. The conditioning regimen consisted of cyclophosphamide (60 mg/kg/d, on d -4 and -3), anti-thymocyte globulin (2·5 mg/kg/d, on d -5 to -2) and total body irradiation (2·5 Gy×2/d, on d -2 and -1). Patients received cyclosporine and methotrexate for prophylaxis of graft-versus-host disease (GVHD), except for the last four who received tacrolimus instead of cyclosporine. Donor/recipient pairs were identical for HLA class I and II antigens by serological typing, but four pairs were found to have a mismatch at the HLA-A, -B or -DRB1 locus by high-resolution typing. All patients achieved rapid engraftment and are alive at 2-86 months after transplantation (median follow-up, 51 months). Moderate to severe acute GVHD occurred in 5 out of 15 patients (33%); only one patient developed extensive chronic GVHD. Considering our encouraging results, unrelated donor transplantation for SAA is recommended as a salvage therapy in non-responders to IST.

Original languageEnglish
Pages (from-to)706-711
Number of pages6
JournalBritish Journal of Haematology
Volume114
Issue number3
DOIs
Publication statusPublished - Oct 22 2001
Externally publishedYes

Fingerprint

Unrelated Donors
Antilymphocyte Serum
Aplastic Anemia
Whole-Body Irradiation
Cyclophosphamide
Transplantation
Bone Marrow
Graft vs Host Disease
HLA Antigens
Immunosuppressive Agents
Cyclosporine
Salvage Therapy
Histocompatibility Antigens Class I
Histocompatibility Antigens Class II
Tacrolimus
Bone Marrow Transplantation
Methotrexate
Tissue Donors
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. / Kojima, Seiji; Inaba, Jun; Yoshimi, Ayami; Takahashi, Yoshiyuki; Watanabe, Nobuhiro; Kudo, Kazuko; Horibe, Keizo; Maeda, Naoko; Kato, Koji; Matsuyama, Takaharu.

In: British Journal of Haematology, Vol. 114, No. 3, 22.10.2001, p. 706-711.

Research output: Contribution to journalArticle

Kojima, Seiji ; Inaba, Jun ; Yoshimi, Ayami ; Takahashi, Yoshiyuki ; Watanabe, Nobuhiro ; Kudo, Kazuko ; Horibe, Keizo ; Maeda, Naoko ; Kato, Koji ; Matsuyama, Takaharu. / Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. In: British Journal of Haematology. 2001 ; Vol. 114, No. 3. pp. 706-711.
@article{29dddfb05846412492ca129a0536e716,
title = "Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation",
abstract = "We report a favourable outcome in 15 patients with severe aplastic anaemia (SAA) who were <20 years of age and who underwent bone marrow transplantation (BMT) from a human leucocyte antigen (HLA)-matched unrelated donor. All patients were non-responders to intensive immunosuppressive therapy (IST) and were multiply transfused. The conditioning regimen consisted of cyclophosphamide (60 mg/kg/d, on d -4 and -3), anti-thymocyte globulin (2·5 mg/kg/d, on d -5 to -2) and total body irradiation (2·5 Gy×2/d, on d -2 and -1). Patients received cyclosporine and methotrexate for prophylaxis of graft-versus-host disease (GVHD), except for the last four who received tacrolimus instead of cyclosporine. Donor/recipient pairs were identical for HLA class I and II antigens by serological typing, but four pairs were found to have a mismatch at the HLA-A, -B or -DRB1 locus by high-resolution typing. All patients achieved rapid engraftment and are alive at 2-86 months after transplantation (median follow-up, 51 months). Moderate to severe acute GVHD occurred in 5 out of 15 patients (33{\%}); only one patient developed extensive chronic GVHD. Considering our encouraging results, unrelated donor transplantation for SAA is recommended as a salvage therapy in non-responders to IST.",
author = "Seiji Kojima and Jun Inaba and Ayami Yoshimi and Yoshiyuki Takahashi and Nobuhiro Watanabe and Kazuko Kudo and Keizo Horibe and Naoko Maeda and Koji Kato and Takaharu Matsuyama",
year = "2001",
month = "10",
day = "22",
doi = "10.1046/j.1365-2141.2001.02992.x",
language = "English",
volume = "114",
pages = "706--711",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation

AU - Kojima, Seiji

AU - Inaba, Jun

AU - Yoshimi, Ayami

AU - Takahashi, Yoshiyuki

AU - Watanabe, Nobuhiro

AU - Kudo, Kazuko

AU - Horibe, Keizo

AU - Maeda, Naoko

AU - Kato, Koji

AU - Matsuyama, Takaharu

PY - 2001/10/22

Y1 - 2001/10/22

N2 - We report a favourable outcome in 15 patients with severe aplastic anaemia (SAA) who were <20 years of age and who underwent bone marrow transplantation (BMT) from a human leucocyte antigen (HLA)-matched unrelated donor. All patients were non-responders to intensive immunosuppressive therapy (IST) and were multiply transfused. The conditioning regimen consisted of cyclophosphamide (60 mg/kg/d, on d -4 and -3), anti-thymocyte globulin (2·5 mg/kg/d, on d -5 to -2) and total body irradiation (2·5 Gy×2/d, on d -2 and -1). Patients received cyclosporine and methotrexate for prophylaxis of graft-versus-host disease (GVHD), except for the last four who received tacrolimus instead of cyclosporine. Donor/recipient pairs were identical for HLA class I and II antigens by serological typing, but four pairs were found to have a mismatch at the HLA-A, -B or -DRB1 locus by high-resolution typing. All patients achieved rapid engraftment and are alive at 2-86 months after transplantation (median follow-up, 51 months). Moderate to severe acute GVHD occurred in 5 out of 15 patients (33%); only one patient developed extensive chronic GVHD. Considering our encouraging results, unrelated donor transplantation for SAA is recommended as a salvage therapy in non-responders to IST.

AB - We report a favourable outcome in 15 patients with severe aplastic anaemia (SAA) who were <20 years of age and who underwent bone marrow transplantation (BMT) from a human leucocyte antigen (HLA)-matched unrelated donor. All patients were non-responders to intensive immunosuppressive therapy (IST) and were multiply transfused. The conditioning regimen consisted of cyclophosphamide (60 mg/kg/d, on d -4 and -3), anti-thymocyte globulin (2·5 mg/kg/d, on d -5 to -2) and total body irradiation (2·5 Gy×2/d, on d -2 and -1). Patients received cyclosporine and methotrexate for prophylaxis of graft-versus-host disease (GVHD), except for the last four who received tacrolimus instead of cyclosporine. Donor/recipient pairs were identical for HLA class I and II antigens by serological typing, but four pairs were found to have a mismatch at the HLA-A, -B or -DRB1 locus by high-resolution typing. All patients achieved rapid engraftment and are alive at 2-86 months after transplantation (median follow-up, 51 months). Moderate to severe acute GVHD occurred in 5 out of 15 patients (33%); only one patient developed extensive chronic GVHD. Considering our encouraging results, unrelated donor transplantation for SAA is recommended as a salvage therapy in non-responders to IST.

UR - http://www.scopus.com/inward/record.url?scp=17944369592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944369592&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2001.02992.x

DO - 10.1046/j.1365-2141.2001.02992.x

M3 - Article

C2 - 11553002

AN - SCOPUS:17944369592

VL - 114

SP - 706

EP - 711

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -